Skip to main content
Clinical Trials/NCT04073940
NCT04073940
Unknown
Not Applicable

Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis

University of Illinois at Urbana-Champaign1 site in 1 country30 target enrollmentAugust 29, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis, Relapsing-Remitting
Sponsor
University of Illinois at Urbana-Champaign
Enrollment
30
Locations
1
Primary Endpoint
Structural Connectivity
Last Updated
6 years ago

Overview

Brief Summary

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) affecting roughly 900,000 people in the United States that frequently results in impaired mobility. The majority of people with MS express that impaired mobility the most difficult aspect of living with the disease. Ataxia is one aspect of impaired mobility experienced by approximately 80% of persons with MS. Despite $9 billion in drug costs to patients with MS in the U.S., in 2012 alone, standard pharmacological treatment for MS is ineffective in restoring mobility and decreasing ataxia. The PI designed a targeted ballet program requiring motor learning of complex movements that mitigated ataxia and improved balance in patients with MS in a pilot study. The improvements obtained were approximately five times larger than those reported by other physical rehabilitation interventions. However, understanding these changes requires determining whether there are underlying changes in the brain after participation in the targeted ballet program.

This project involves persons with mild-to-moderate MS that present ataxia in their movement. We will compare the brain connectivity of participants in the targeted ballet program before and after the 16-week, twice per week, hourly participation intervention. Brain images will be obtained with magnetic resonance imaging while each participant rests with the eyes open. As a secondary outcome, measures of movement quality, ataxia, and balance will be taken to better understand the effects of the targeted ballet program on motor function, wellness, and the brains of persons with mild to moderate MS. Test on movement will include a 10 meter walk with motion tracking, a balance test using a force plate, and clinical tests of ataxia, balance, and walking speed. We will also assess changes in wellness with standard questionnaires.

Detailed Description

Multiple sclerosis (MS) is an autoimmune-mediated disease with brain demyelination and axonal loss that result in impaired mobility, which affects an estimated 75% of people with MS and is reported as the most difficult aspect of living with MS. An estimated 900,000 people in the U.S. suffer from MS, which has no known cure. In 2012 alone, drug costs to patients with MS in the U.S. were $9 billion. Despite the high costs, pharmacological interventions do not induce myelination so motor impairments persist. The PI designed a ballet-based program for complex motor learning delivered in a group setting. Our previous work provides evidence that the targeted ballet program increased balance and walking scores by 42% and decreased clinical ataxia scores by 58% over a period of 16 weeks and 32 hours of instruction. However, understanding these changes requires determining whether there are underlying changes in the brain after participation in the targeted ballet program. The goal of this proposal is to provide evidence of improvements in brain connectivity measures after participation in the targeted ballet program in persons with MS. As secondary outcomes, we will assess motor function and wellness after participation in the targeted ballet program in persons with MS.

Registry
clinicaltrials.gov
Start Date
August 29, 2019
End Date
January 15, 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Citlali Lopez-Ortiz

Assistant Professor

University of Illinois at Urbana-Champaign

Eligibility Criteria

Inclusion Criteria

  • Age between 18-64
  • Informed consent obtained
  • Confirmation of relapsing remitting MS (RRMS) diagnosis by the participant's neurologist
  • Presence of ataxia determined by the International Cooperative Ataxia Rating Scale (ICARS) recommended by the NIH and the Ataxia Neuropharmacology Committee of the World Federation of Neurology with a score greater or equal to 7
  • Expanded Disability Status Scale (EDSS) scores of 1.0-6.5 based on an examination by a Neurostatus certified examiner for indicating walking impairment
  • Relapse free in the previous 30 days
  • Approval for exercise training.

Exclusion Criteria

  • Presence of severe cognitive impairment based on an oral Symbol Digit Modalities Test (SDMT) score of less than 23, or the Montreal Cognitive Assessment (MoCA) Test less than 22
  • Inability to understand experimental instructions presented in English
  • Pregnancy
  • Education level less than 8th grade - due to concerns about understanding the study and consent form
  • Change in use of disease modifying therapy in the previous 6 months,
  • Initiation of Ampyra or other medications that influence walking and mobility within the previous 30 days,
  • History of brain injury or central nervous system disease other than multiple sclerosis - this will be determined from gross anatomical abnormalities in the images or from medical history on Biomedical Imaging Center (BIC) screening form,
  • Presence of orthopedic conditions,
  • The presence of any skin conditions preventing the safe usage of motion tracking marker adhesives
  • The presence of conditions which would contra-indicate MRI: prior surgeries and/or implant of pacemakers, pacemaker wires, artificial heart valve, brain aneurysm surgery, middle ear implant, non-removable hearing aid or jewelry, braces or extensive dental work, cataract surgery or lens implant, implanted mechanical or electrical device, artificial limb or joint; foreign metallic objects in the body such as bullets, BB's, shrapnel, or metalwork fragments; pregnancy, claustrophobia, uncontrollable shaking, or inability to lie still for 2 hours.

Outcomes

Primary Outcomes

Structural Connectivity

Time Frame: Before and after the 16-week intervention period

Mean strength, global efficiency, and mean clustering coefficient for the networks seeded from the regions of interest: the fornix, supplemental motor area, corpus callosum, orbitofrontal cortex, putamen, and cerebellum. Using Probtrackx2 in network mode, the output is a connectivity martix, which contains the number of streamlines from each seed volume (e.g., all voxels in insula cortex) that reached all other target regions. Structural connections will be normalized by the average volume of each region of interest (ROI) comprising the particular pathway to eliminate bias induced from larger ROI's. Additionally, the structural connectomes will be symmetrized by averaging the two connections in the connectivity matrix corresponding to the pair of ROI's (where one connection is ROI 1 as seed and ROI 2 as target, and the other connection flips the seed and target labels).

Resting-State Functional Connectivity

Time Frame: Before and after the 16-week intervention period

We will acquire one 8 minute scan for resting state functional connectivity analysis, during which participants will be instructed to maintain their eyes open and focus on a fixation point as was done in Bollaert et al. 2018. We will use a modified version of the Duke Brain Imaging and Analysis Center's (BIAC) resting-state functional connectivity to find the correlation coefficients of the resting-state blood oxygen level-dependent activation of the 68 regions from Freesurfer's parcellation and the 34 regions of the cerebellum from the spatially unbiased atlas template of the cerebellum and brainstem (SUIT) parcellation. We will use the brain connectivity toolbox (BCT) to form graph-theoretical measures of the network for evaluating changes in connectivity.

Secondary Outcomes

  • International Cooperative Ataxia Rating Scale (ICARS)(Before and after the 16-week intervention period)
  • Mini Balance Evaluation Systems Test (Mini-BESTest)(Before and after the 16-week intervention period)
  • 10-Meter Walk Test (10MWT)(Before and after the 16-week intervention period)
  • World Health Organization Disability Assessment Schedule (WHODAS)(Before and after the 16-week intervention period)
  • World Health Organization Five Well-Being Index (WHO-5).(Before and after the 16-week intervention period)
  • Smoothness Index(Before and after the 16-week intervention period)
  • Step-to-Stand Stabilization Task(Before and after the 16-week intervention period)

Study Sites (1)

Loading locations...

Similar Trials